A Study of the Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Features of Atypical/Dysplastic Nevi in Patients with Stage IIB-IIIC Melanoma

Inclusion Criteria

• * Subjects must have at least two atypical nevi of >= 4 mm diameter * Subjects must have a current documented history of melanoma * Subject must be >= 18 years and if female of childbearing potential, must agree to practice effective contraception per institutional SOC if sexually active * Subjects will have been deemed candidates for adjuvant therapy with anti-PD1 therapy * Subjects must give written informed consent to participate in this study with consent signed and dated prior to entry into trial

Exclusion Criteria

• * Patients with non-malignant diseases or indications that would preclude the administration of anti-PD1 therapy such as significant immune suppression or active autoimmune disease requiring disease modifying, immunosuppressive therapy, will be ineligible * Patients who have previously received anti-PD1 therapy * Patients with history of other active, non-melanoma cancers * Patients who are receiving other anti-neoplastic therapy